UTHR
$540.02
United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally.
Intraday
Recent News
This Biotech Stock Surged 75% Last Quarter and Pulled a New $9 Million Investment
Vera Therapeutics develops clinical-stage therapies for serious immunological diseases, with a lead candidate targeting kidney disorders.
This Life Sciences Supplier Has Plunged 50% in a Year, but One Fund Bought Up $28 Million More in Stock
Avantor delivers laboratory materials and specialized services to biopharma, healthcare, and advanced technology clients worldwide.
Tyvaso IPF Data In NEJM Reframes United Therapeutics Growth Potential
United Therapeutics (NasdaqGS:UTHR) reported full Phase 3 TETON-2 trial data for nebulized Tyvaso in idiopathic pulmonary fibrosis, published in the New England Journal of Medicine. The study showed meaningful preservation of lung function and a reduction in clinical worsening for IPF patients treated with Tyvaso. If approved by the FDA, Tyvaso could become the first and only inhaled anti fibrotic treatment for IPF, expanding United Therapeutics' potential addressable market. United...
United Therapeutics Stock Surges 32% in 6 Months: Here's Why
UTHR shares jump 32% in six months as Tyvaso sales surge, earnings grow and Phase III TETON-2 data open a potential new market in IPF.
United Therapeutics (UTHR) Surges 10.7%: Is This an Indication of Further Gains?
United Therapeutics (UTHR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.